IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ALTOMARE, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 265
NA - Nord America 258
EU - Europa 189
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 715
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 258
SG - Singapore 141
CN - Cina 65
IT - Italia 63
DE - Germania 50
TR - Turchia 46
CZ - Repubblica Ceca 30
UA - Ucraina 12
RU - Federazione Russa 10
GB - Regno Unito 8
IN - India 7
FI - Finlandia 5
HK - Hong Kong 4
IE - Irlanda 2
PT - Portogallo 2
AU - Australia 1
BE - Belgio 1
EC - Ecuador 1
FR - Francia 1
JP - Giappone 1
KG - Kirghizistan 1
LV - Lettonia 1
MA - Marocco 1
NL - Olanda 1
NO - Norvegia 1
PL - Polonia 1
SE - Svezia 1
Totale 715
Salva come PNG Salva come JPEG
Città #
Singapore 121
Istanbul 46
Boardman 35
Fairfield 32
Romola 24
Woodbridge 21
Houston 17
Shanghai 16
Brno 15
Olomouc 15
Ashburn 12
Munich 12
Jacksonville 10
Wilmington 10
Seattle 9
Cambridge 8
New York 8
Chandler 7
Mumbai 7
Beijing 6
Dearborn 5
Helsinki 5
Padova 5
Hong Kong 4
Nanjing 4
Princeton 4
Ann Arbor 3
Bergamo 3
Jinan 3
Santa Clara 3
Des Moines 2
Dublin 2
Leipzig 2
Milan 2
Nürnberg 2
Palermo 2
Pavia 2
San Diego 2
San Francisco 2
Venice 2
Augusta 1
Bishkek 1
Bologna 1
Brescia 1
Brussels 1
Changsha 1
Chiba 1
Guayaquil 1
Hangzhou 1
Hebei 1
Kunming 1
Lisbon 1
Los Angeles 1
Nanchang 1
Naples 1
New Orleans 1
Oslo 1
Philadelphia 1
Rabat 1
Riga 1
St Petersburg 1
Stockholm 1
Tianjin 1
Volzhsky 1
Walnut 1
Washington 1
Totale 516
Salva come PNG Salva come JPEG
Nome #
Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation 146
Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic. 137
Comparison of visual criteria for amyloid-pet reading: Could criteria merging reduce inter-rater variability? 21
Neuropsychiatric Symptoms in Frontotemporal Dementia: More Than Just Noise? 15
Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia 14
European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus 14
Applying the ATN scheme in a memory clinic population: The ABIDE project 14
Home-based transcranial alternating current stimulation (tACS) in Alzheimer’s disease: rationale and study design 13
Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6 13
Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders 13
Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia 13
Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease 12
Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies 12
Clinical utility of FDG-PET for the clinical diagnosis in MCI 12
Dementia risk communication. A user manual for Brain Health Services—part 3 of 6 12
Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease 11
Brain atrophy in Alzheimer's Disease and aging 11
Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia 11
Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study 11
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial 11
Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia 11
Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6 10
AMYPAD Diagnostic and Patient Management Study: Rationale and design 10
Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design 10
The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact 10
Plasma biomarkers for Alzheimer's disease: A field-test in a memory clinic 10
Societal and equity challenges for Brain Health Services. A user manual for Brain Health Services—part 6 of 6 10
Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults with Subjective Cognitive Decline 10
Protocols for cognitive enhancement. A user manual for Brain Health Services—part 5 of 6 10
Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe 10
Medial temporal lobe atrophy and posterior atrophy scales normative values 10
Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study 10
Comment: Is a Large-Scale Screening for Alzheimer's Disease Possible? Yes, in a Few Years 10
Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer’s disease 9
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum 9
Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET 9
Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 9
Dementia prevention in memory clinics: recommendations from the European task force for brain health services 9
Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison 8
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised 8
Prognostic value of Alzheimer’s biomarkers in mild cognitive impairment: the effect of age at onset 8
Feasibility of a standard cognitive assessment in European academic memory clinics 7
The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey 6
Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study 6
Quantification of [18F]florbetaben amyloid-PET imaging in a mixed memory clinic population: The ABIDE project 6
Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study 6
Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives 6
Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease 6
Multitracer model for staging cortical amyloid deposition using PET imaging 5
Time to Diagnosis and Its Predictors in Syndromes Associated With Frontotemporal Lobar Degeneration 4
Totale 768
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.506
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.506
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202059 0 0 0 0 6 12 10 9 7 9 2 4
2020/202144 0 10 11 3 2 2 2 3 3 3 4 1
2021/202222 1 0 1 2 0 0 1 2 5 2 2 6
2022/202316 3 1 0 3 1 5 0 0 3 0 0 0
2023/2024214 3 2 7 0 0 11 2 1 5 55 16 112
2024/2025310 31 1 57 148 73 0 0 0 0 0 0 0
Totale 768